Abstract:ABSTRACT The rapid evolution of SARS-CoV-2 variants highlights the need for new therapies to prevent disease spread. SARS-CoV-2, like SARS-CoV-1, uses the human cell surface protein angiotensin-converting enzyme 2 (ACE2) as its native receptor. Here, we design and characterize a mutant ACE2 that enables rapid affinity purification of a dimeric protein by altering the active site to prevent autoproteolytic digestion of a C-terminal His 10 epitope tag. In cultured cells, mutant ACE2 competitively inhibits lentiviral vectors pseudotyped with spikes from multiple SARS-CoV-2 variants and infectious SARS-CoV-2. Moreover, the protein can be nebulized and retains virus-binding properties. We developed a system for the delivery of aerosolized ACE2 to K18-hACE2 mice and demonstrated protection by our modified ACE2 when delivered as a prophylactic agent. These results show proof-of-concept for an aerosolized delivery method to evaluate anti-SARS-CoV-2 agents in vivo and suggest a new tool in the ongoing fight against SARS-CoV-2 and other ACE2-dependent viruses. IMPORTANCE The rapid evolution of SARS-CoV-2 variants poses a challenge for immune recognition and antibody therapies. However, the virus is constrained by the requirement that it recognizes a human host receptor protein. A recombinant ACE2 could protect against SARS-CoV-2 infection by functioning as a soluble decoy receptor. We designed a mutant version of ACE2 with impaired catalytic activity to enable the purification of the protein using a single affinity purification step. This protein can be nebulized and retains the ability to bind the relevant domains from SARS-CoV-1 and SARS-CoV-2. Moreover, this protein inhibits viral infection against a panel of coronaviruses in cells. Finally, we developed an aerosolized delivery system for animal studies and show the modified ACE2 offers protection in an animal model of COVID-19. These results show proof-of-concept for an aerosolized delivery method to evaluate anti-SARS-CoV-2 agents in vivo and suggest a new tool in the ongoing fight against SARS-CoV-2.

Functionalized protein microparticles targeting hACE2 as a novel preventive strategy for SARS-CoV-2 infection

Potent prophylactic and therapeutic efficacy of recombinant human ACE2-Fc against SARS-CoV-2 infection in vivo

Neutralization of SARS-CoV-2 pseudovirus using ACE2-engineered extracellular vesicles

Protective Efficacy of Novel Engineered Human ACE2-Fc Fusion Protein Against Pan-SARS-CoV-2 Infection In Vitro and in Vivo

HACE2-Exosome-Based Nano-Bait for Concurrent SARS-CoV-2 Trapping and Antioxidant Therapy

“Molecular Masks” for ACE2 to Effectively and Safely Block SARS-CoV-2 Virus Entry

Potential Therapeutic Approaches for the Early Entry of SARS-CoV-2 by Interrupting the Interaction Between the Spike Protein on SARS-CoV-2 and Angiotensin-Converting Enzyme 2 (ACE2)

An Effective Platform for SARS-CoV-2 Prevention by Combining Neutralization and RNAi Technology

Potential use of the S-protein–Angiotensin converting enzyme 2 binding pathway in the treatment of coronavirus disease 2019

Antigen Spatial-Matching Polyaptamer Nanostructure to Block Coronavirus Infection and Alleviate Inflammation

Engineering Extracellular Vesicles Enriched with Palmitoylated ACE2 as COVID‐19 Therapy

Development of nanoparticles incorporated with quercetin and ACE2-membrane as a novel therapy for COVID-19

Membrane Nanoparticles Derived from ACE2-Rich Cells Block SARS-CoV-2 Infection.

Engineering Mesenchymal Stromal Cells with Neutralizing and Anti-Inflammatory Capability Against SARS-CoV-2 Infection.

Engineered Trimeric ACE2 Binds Viral Spike Protein and Locks It in “Three-Up” Conformation to Potently Inhibit SARS-CoV-2 Infection

Targeting Heparan Sulfate Proteoglycan-Assisted Endocytosis As a COVID-19 Therapeutic Option

Development of a mutant aerosolized ACE2 that neutralizes SARS-CoV-2 in vivo

Utilizing noncatalytic ACE2 protein mutant as a competitive inhibitor to treat SARS-CoV-2 infection

Ångstrom-scale silver particles potently combat SARS-CoV-2 infection by suppressing the ACE2 expression and inflammatory responses

Inhalable nanocatchers for SARS-CoV-2 inhibition

Discovery of Small Anti‐ACE2 Peptides to Inhibit SARS‐CoV‐2 Infectivity